AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:18 2025-01-17 EST			5-day change	1st Jan Change
10,938.00 ^GBX	+0.87%		-0.40%	+4.49%

11:16am	USA: 15 new drugs on the negotiation list	CF
10:56am	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT

AstraZeneca, Ericsson, Business Sweden, Healthcare Partners Form Global Health Innovation Network

November 20, 2024 at 06:55 am

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about AstraZeneca PLC

USA: 15 new drugs on the negotiation list	11:16am	CF
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	10:56am	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	09:19am	MT
AstraZeneca overhauls management of its China division, FT reports	09:12am	RE
Astrazeneca Says Mantle Cell Lymphoma Combination Treatment Receives FDA Approval	08:27am	MT
FTSE 100 : Merger murmurs and Chinese data boost stocks	04:07am
AstraZeneca's Calquence gets US approval for mantle cell lymphoma	03:18am	AN
AstraZeneca: Calquence approved for LCM by the FDA	03:00am	CF
Stocks called up but UK retail sales miss forecasts	02:50am	AN
AstraZeneca Gets US FDA Nod for Lymphocytic Leukemia Treatment Calquence	02:33am	MT
Astrazeneca Announces Approval of Calquence (Acalabrutinib) in Combination with Bendamustine and Rituximab in the US for the Treatment of Adult Patients	02:00am	CI
Cellectis Files for Resale of 44 Million Company Shares by AstraZeneca	01-15	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	01-15	ZD
Stockholm Bullets - Millicom rises on new dividend policy	01-15	FW
Hutchmed lung cancer treatment Orpathys approved in China	01-14	AN
Two experts give tips on dividend portfolios	01-14	FW
Swedish stocks in North America - Autoliv up 1.1 percent	01-14	FW
Hutchmed Announces NMPA Full Approval for Orpathys (Savolitinib) in China for Patients with Locally Advanced or Metastatic Met Exon 14 NSCLC	01-13	CI
Philips CEO sees subdued China sales this year	01-13	RE
Global markets live: Apple, Johnson & Johnson, Meta, Amazon, The Hershey, Eli Lilly...	01-13
Synthego Signs Strategic Agreement with Astrazeneca to License CRISPR Gene Editing Enzyme	01-13	CI
Astrazeneca Receives Priority Review for Datopotamab Deruxtecan in Non-Small Cell Lung Cancer	01-13	MT
ASTRAZENECA : Goldman Sachs reiterates its Buy rating	01-13	ZD
Deutsche Bank cuts Direct Line to 'hold'	01-13	AN
AstraZeneca and Daiichi Sankyo cheer priority US review of cancer drug	01-13	AN

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2025-02-06 - Q4 2024 Earnings Release

More about the company